AKT1 and breast carcinoma: Instead, these therapeutics have been used in ER+/HER2− postmenopausal breast cancer patients who are refractory to endocrine therapies—acquired genetic alterations activating the PI3K–AKT–mTOR pathway frequently drive resistance to endocrine therapies (Nunnery and Mayer, 2020).